3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide;hydrate;hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide;hydrate;hydrochloride
• 化学式: C6H11Cl2N7O2
• 分子量: 284.1
• InChiKey: WDZJJRLYFQNCQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.69
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  160
• 氢给体数：
  6
• 氢受体数：
  6

文献信息

• METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS
  申请人：GRIFFITH UNIVERSITY

  公开号：US20210069180A1

  公开（公告）日：2021-03-11

  In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.

  在一个方面，该发明涉及一种治疗方法，所述方法选自以下组合：(a)治疗被识别或诊断为患有肌无力性脑脊髓炎/慢性疲劳综合征（ME/CFS）的受试者的症状，例如疼痛；(b)治疗具有TRPM3离子通道活性异常的受试者的症状，例如疼痛；(c)恢复具有TRPM3离子通道活性异常的受试者的NK细胞功能；以及(d)恢复具有TRPM3离子通道活性异常的受试者的钙稳态。该方法包括向受试者施用来自以下组合的至少一种治疗化合物的治疗有效量的步骤：(i)阿片受体拮抗剂；(ii)阿片拮抗剂；以及(iii)恢复TRPM3离子通道活性的治疗化合物。在某些实施例中，治疗化合物是盐酸纳曲酮。
• THERAPEUTIC USES OF SGLT2 INHIBITORS
  申请人：Seed Brian

  公开号：US20110077212A1

  公开（公告）日：2011-03-31

  Provided are methods of using one or more SGLT2 inhibitors, independently or in combination, for treating edema or reducing fluid retention. The invention also provides methods of using one or more SGLT2 inhibitors for the preparation of a medicament for treating edema or fluid retention. Methods are also provided for treating diabetes with an amount of one or more SGLT2 inhibitors and one or more PPAR-gamma agonists.

  提供了使用一种或多种SGLT2抑制剂的方法，独立使用或结合使用，用于治疗水肿或减少液体潴留。本发明还提供了使用一种或多种SGLT2抑制剂制备治疗水肿或液体潴留药物的方法。还提供了使用一种或多种SGLT2抑制剂和一种或多种PPAR-γ激动剂治疗糖尿病的方法。
• Nitrobenzaldehyde proton release for manipulation of cellular acidosis
  申请人：THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US10946096B2

  公开（公告）日：2021-03-16

  Certain embodiments are directed to photo-activated compounds for the manipulation of pH in a cell. In certain aspects the photo-activated compound is 2-nitrobenzaldehyde (NBA). Photo-activated compounds can be used as a targeted therapy for a variety of disease states and conditions, such as cancer.

  某些实施方案涉及用于调节细胞 pH 值的光活化化合物。在某些方面，光活化化合物是 2-硝基苯甲醛（NBA）。光活化化合物可用作癌症等多种疾病的靶向治疗。
• EXTRACORPOREAL LUNG TREATMENT WITH A CYCLIC PEPTIDE OF FORMULA X1-GQRETPEGAEAKPWY-X2
  申请人：APEPTICO Forschung und Entwicklung GmbH

  公开号：EP2988769B1

  公开（公告）日：2020-05-27
• PHARMACEUTICAL COMPOSITION COMPRISING A CYCLIC PEPTIDE OF FORMULA X1 -GQRETPEGAEAKPWY-X2 AND USE FOR EXTRACORPOREAL LUNG TREATMENT
  申请人：APEPTICO Forschung und Entwicklung GmbH

  公开号：EP2988769A1

  公开（公告）日：2016-03-02